eMBR Genomics and Axio BioPharma Collaborate to Launch MKLP1 Pro™ Antibodies for Enhanced Cancer Research eMBR Genomics partners with Axio BioPharma to commercialize MKLP1 Pro™ antibodies that advance cancer detection and cellular research globally.

eMBR Genomics and Axio BioPharma Collaborate to Launch MKLP1 Pro™ Antibodies for Enhanced Cancer Research #USA #eMBR_Genomics #Axio_BioPharma #MKLP1_Pro #Madison,_Wisconsin